Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus.
Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonimmunosuppressed patients. Patients present with lymphomatous effusions in serous cavities--pleura, pericardium, or peritoneum--without any identifiable tumor mass. PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts. A standard treatment for PEL has not yet been identified. We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.
Won
Jong-Ho
JH
Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea.
Han
Seung-Hyo
SH
Bae
Sang-Byung
SB
Kim
Chan-Kyu
CK
Lee
Nam-Su
NS
Lee
Kyu-Taeg
KT
Park
Sung-Kyu
SK
Hong
Dae-Sik
DS
Lee
Dong-Wha
DW
Park
Hee-Sook
HS
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018572:Disease-Free Survival; D006679:HIV Seropositivity; D006338:Heart Neoplasms / Q000150:complications / Q000628:therapy*; D006801:Humans; D008223:Lymphoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010490:Pericardial Effusion / Q000150:complications / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous